The SPOTLIGHT study’s phase III findings on zolbetuximab plus mFOLFOX6 as first-line treatment for patients with the biomarker claudin-18.2–positive and HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma were presented by Shitara et al at the 2023 ASCO Gastrointestinal Cancers Symposium (Abstract LBA292).
